Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187720 · ClinicalTrials.gov registry record · Phase 4
Genetic Basis for Variation in the Renal Elimination of Metformin
A Phase 4 study of Other Conditions That May Be A Focus of Clinical Attention, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT00187720: Completed Phase 4 study of Other Conditions That May Be A Focus of Clinical Attention, sponsored by University of California, San Francisco.
NCT00187720 is a Phase 4 study of Other Conditions That May Be A Focus of Clinical Attention that has completed, run by University of California, San Francisco. The registered enrollment target is 23 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00187720, a Phase 4 study of Other Conditions That May Be A Focus of Clinical Attention, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. We will study individuals with particular genotypes of the human organic cation transporter, (hOCT2), to test the hypothesis that genetic variation in hOCT2 is associated with variation in the renal clearance of the antidiabetic agent, metformin.
Primary Outcome
To test whether individuals with genetic variants of the human organic cation transporter, OCT2, exhibit altered renal elimination of metformin we will measure the difference in renal clearance between reference and variant groups.
Conditions Studied
Interventions
- DRUG Metformin
Study Locations (1)
California
- San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2002-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
What the finished NCT00187720 record still lists
NCT00187720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Other Conditions That May Be A Focus of Clinical Attention appearing as the primary indexed condition, and to 1 intervention - of which Metformin is the first listed.
NCT00187720 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00187720 about?
NCT00187720 is a clinical study titled "Genetic Basis for Variation in the Renal Elimination of Metformin". The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. We will study individuals with particular genotypes of the human organic cation transporter, (hOCT2), to test the hypothesis that genetic variation in hOCT2 is associat...
What is the current status of trial NCT00187720?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2002-05. Estimated completion is 2008-04.
What conditions does trial NCT00187720 study?
This clinical trial studies the following conditions: Other Conditions That May Be A Focus of Clinical Attention.
What interventions are being tested in trial NCT00187720?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT00187720?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00187720 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00187720's enrollment target sits among peer trials
23 1725th of 2000 higher than 271 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia